Symmetry Medical Inc. has announced that its subsidiary Symmetry Surgical, Inc. (SSi) has completed an exclusive distribution agreement in Italy with Biocommerciale Srl. In this new partnership, Biocommerciale will distribute Symmetry Surgical’s portfolio of surgical instruments, which includes leading brands and products formerly part of Codman surgical instruments, SSi and Olsen Medical.
Symmetry Signs Agreement With Italian Company
1 min read Premium comments
Secondary
Biocommerciale has more than 30 years of experience working with hospitals and healthcare professionals in the Italian marketplace, and distributes medical devices and surgical instruments as well as sterile processing and operating room supplies to more than 1, 000 hospitals, clinics and medical facilities.
In the November 26, 2012 news release Chris Huntington, chief operating officer of Symmetry Surgical, said, “We are excited to partner with Biocommerciale and expand our growing global presence into Italy, giving medical professionals access to our portfolio of new and innovative surgical instruments. We look forward to driving growth in the Italian market from our existing brands, as well as innovations resulting from our focus on new medical devices and services that benefit surgeons and clinicians—and their patients—worldwide.”
Huntington told OTW,
As projected in our integration plan for the surgical instruments business we acquired in 2011 from Codman, we are excited about the opportunity to expand our Symmetry Surgical presence in Italy, a key European market. Biocommerciale is a high-quality, respected company in Italy, and is well positioned to drive adoption of Symmetry Surgical’s portfolio throughout the country as we transition from our support services with Codman. We look forward to continuing to strengthen our relationship and introduce new products into the Italian market in the future.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.